Get the Stockscreener App
2.2078
0.23%
0.0078
Macrogenics Inc stock is traded at $2.2078, with a volume of 55,214.
It is up +0.23% in the last 24 hours and down -13.87% over the past month.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
See More
Previous Close:
$2.20
Open:
$2.24
24h Volume:
55,214
Relative Volume:
0.10
Market Cap:
$138.08M
Revenue:
$139.77M
Net Income/Loss:
$-97.62M
P/E Ratio:
-1.3973
EPS:
-1.58
Net Cash Flow:
$-61.71M
1W Performance:
-2.86%
1M Performance:
-13.87%
6M Performance:
-40.41%
1Y Performance:
-86.27%
1-Day Range:
$2.185
$2.24
1-Week Range:
$2.16
$2.485
52-Week Range:
$2.16
$19.54
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
2.205 | 138.08M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
509.27 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
679.00 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.26 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.85 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.39 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-01-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-31-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| May-10-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-10-24 | Downgrade | Stifel | Buy → Hold |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| Apr-26-24 | Initiated | B. Riley Securities | Buy |
| Apr-09-24 | Upgrade | TD Cowen | Hold → Buy |
| Mar-04-24 | Reiterated | BTIG Research | Buy |
| Feb-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-04-22 | Initiated | SMBC Nikko | Outperform |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
| Dec-22-20 | Resumed | H.C. Wainwright | Buy |
| Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-26-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Guggenheim | Neutral |
| Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
| Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
| Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-31-18 | Initiated | Evercore ISI | Outperform |
| Mar-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
MacroGenics (MGNX) to Release Quarterly Earnings on Thursday - Defense World
MGNX LAWSUIT ALERT: Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
MacroGenics at Barclays Conference: Strategic Insights on Pipeline and Partnerships - Investing.com
MGNX Deadline: MGNX Investors with Losses in Excess of $100K Hav - GuruFocus.com
MacroGenics at Leerink’s Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
MacroGenics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before September 24, 2024 to Discuss Your RightsMGNX - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc. (MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call - GlobeNewswire
MacroGenics at TD Cowen Conference: Strategic Innovations in Immunotherapy - Investing.com India
MacroGenics, Inc. to Announce 2024 Financial Results on March 20, 2025 - Nasdaq
MacroGenics Earnings: Will Q4 Results Reveal Biotech's Growth Trajectory? - StockTitan
MacroGenics Inc earnings beat by $0.33, revenue topped estimates - Investing.com Australia
MacroGenics, Inc. to Host Earnings Call - ACCESS Newswire
Three Companies Surpass Quarterly Earnings Expectations - Evrim Ağacı
Long-Term Investors in shares of MacroGenics, Inc. (NASDAQ: - openPR
Investors Who Lost Money on MacroGenics, Inc. (MGNX) Should Contact Levi & Korsinsky About Pending Class ActionMGNX - ACCESS Newswire
Macrogenics Stock Hits 52-Week Low at $2.31 Amid Sharp Decline - Investing.com India
MacroGenics, Inc. Class Action: Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024MGNX - ACCESS Newswire
Macrogenics Stock Hits 52-Week Low at $2.31 Amid Sharp Decline By Investing.com - Investing.com South Africa
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics, Inc. LawsuitMGNX - ACCESS Newswire
Levi & Korsinsky Reminds MacroGenics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsMGNX - ACCESS Newswire
MACROGENICS Earnings Preview: Recent $MGNX Insider Trading, Hedge Fund Activity, and More - Nasdaq
Levi & Korsinsky Reminds MacroGenics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024MGNX - ACCESS Newswire
MacroGenics, Inc. (MGNX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Shareholders that lost money on MacroGenics, Inc. (MGNX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Sept. 24th Deadline Alert: Investors Who Lost More Than $100,000 With MacroGenics, Inc. (NASDAQ:MGNX) Shares Should Contact the Shareholders Foundation - ACCESS Newswire
MacroGenics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by MacroGenics, Inc. (MGNX) - ACCESS Newswire
MacroGenics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsMGNX - ACCESS Newswire
Shareholder Rights Advocates at Levi & Korsinsky Investigate MacroGenics, Inc. (MGNX) Regarding Possible Securities Fraud Violations - ACCESS Newswire
MacroGenics, Inc. (NASDAQ:MGNX) Not Doing Enough For Some Investors As Its Shares Slump 26% - Simply Wall St
Lost Money on MacroGenics, Inc. (MGNX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of an Investigation into MacroGenics, Inc. (MGNX) Regarding Potential Securities Fraud Allegations - ACCESS Newswire
Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMGNX - ACCESS Newswire
MacroGenics: Stacking Up A Lot Of Headwinds... But It's Fallen Too Far - Seeking Alpha
MacroGenics to Participate in Upcoming Investor Conferences - GlobeNewswire
How Will MacroGenics Address Investors at Three Key Healthcare Conferences? - StockTitan
MacroGenics CEO departure date extended amid search for successor By Investing.com - Investing.com Australia
MacroGenics (MGNX) to Release Earnings on Thursday - Defense World
Shareholders of MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights – MGNX - ACCESS Newswire
MacroGenics CEO departure date extended amid search for successor - Investing.com
MacroGenics Extends CEO’s Separation Agreement - TipRanks
MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of MacroGenics, Inc. to Contact the Firm Today! - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc.(MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Shareholders that lost money on MacroGenics, Inc.(MGNX) should contact Levi & Korsinsky about pending Class ActionMGNX - ACCESS Newswire
Shareholders that Lost Money on MacroGenics, Inc. (MGNX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Investor Network: MacroGenics, Inc. to Host Earnings Call - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics LawsuitMGNX - ACCESS Newswire
MacroGenics, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsMGNX - ACCESS Newswire
Macrogenics VP Beth Smith sells $1,082 in common stock - Investing.com India
Macrogenics VP Beth Smith sells $1,082 in common stock By Investing.com - Investing.com South Africa
Macrogenics Inc Stock (MGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.28%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):